Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to $79.9 million.

  • Madrigal Pharmaceuticals' Share-based Compensation rose 46.68% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.0 million, marking a year-over-year increase of 16.82%. This contributed to the annual value of $79.9 million for FY2024, which is 60.61% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Share-based Compensation stood at $79.9 million for FY2024, which was up 60.61% from $49.7 million recorded in FY2023.
  • Madrigal Pharmaceuticals' Share-based Compensation's 5-year high stood at $79.9 million during FY2024, with a 5-year trough of $20.7 million in FY2020.
  • Its 3-year average for Share-based Compensation is $53.7 million, with a median of $49.7 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first dropped by 8.92% in 2020, then surged by 60.61% in 2024.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Share-based Compensation stood at $20.7 million in 2020, then grew by 29.63% to $26.9 million in 2021, then rose by 17.68% to $31.6 million in 2022, then surged by 57.26% to $49.7 million in 2023, then surged by 60.61% to $79.9 million in 2024.